Clinical Trials to Gain FDA Approval for Computerized Cognitive Training: What Is the Ideal Control Condition?
نویسندگان
چکیده
منابع مشابه
Clinical Trials to Gain FDA Approval for Computerized Cognitive Training: What Is the Ideal Control Condition?
The explosive growth of mobile technologies combined with the rapid rise of aging populations fearful of their risk for Alzheimer’s disease has led to a number of marketed products aimed at enhancing cognitive health. However, an increasing number of product claims that are not substantiated has led regulatory agencies, such as the Federal Trade Commission (FTC), to issue warnings or penalties ...
متن کاملWhat is the Clinical Skills Learning Center?
With shorter periods of hospitalazation, fewer patient beds and more health care facilities in the society, patients are now more acutely ill and highly dependent, causing less opportunities for medical students to practice and learn basic clinical skills. On the other hand, enhanced patient rights and other learnig limitations require that professional education provide not only knowledge and ...
متن کاملWhat Is Cognitive Control?
Imagine yourself at age 3 years—let us say, 3 and a half. It is Saturday morning in late autumn, and instead of being at home in your pajamas watching Scooby-Doo , you fi nd yourself in a university laboratory sitting across from a grown-up, a graduate student named Kay, who would also perhaps prefer to be somewhere else. You think of the Happy Meal you were promised if you got in the car in th...
متن کاملWhat is the Clinical Skills Learning Center (CSLC)?
With shorter periods of hospitalization, fewer in patient beds and more health care facilities in the society patients are now more acutely ill and highly dependent, causing less opportunities for medical students to practice and learn basic clinical skills. On the other hand, enhanced patient rights and other learning limitations require that professional education provide not only knowledge a...
متن کاملFDA Approval Summary: Ramucirumab for Gastric Cancer.
The FDA approved ramucirumab (CYRAMZA; Eli Lilly and Company) for previously treated patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma initially as monotherapy (April 21, 2014) and subsequently as combination therapy with paclitaxel (November 5, 2014). In the monotherapy trial, 355 patients in the indicated population were randomly allocated (2:1) to recei...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Aging Neuroscience
سال: 2016
ISSN: 1663-4365
DOI: 10.3389/fnagi.2016.00249